
Supplementary Fig 1. Geographic distribution of clinical trials



Supplementary Fig 2. Overall ROB by year and by study phase



**Supplementary Appendix 1: Search strategy**

**Pubmed:**

("Amyotrophic Lateral Sclerosis"[Mesh] OR ("Amyotrophic Lateral Sclerosis"[Title/Abstract] OR "Lou Gehrig\*"[Title/Abstract] OR "ALS - Amyotrophic Lateral Sclerosis"[Title/Abstract] OR "ALS Amyotrophic Lateral Sclerosis"[Title/Abstract] OR "Motor Neuron Disease"[Title/Abstract]) AND (((humans[Filter]) AND (english[Filter]))) AND ("Clinical Trials as Topic"[Mesh] OR "clinical trial"[Title/Abstract] OR "RCT"[Title/Abstract] OR "open label"[Title/Abstract] OR "randomi\*"[Title/Abstract] AND ((humans[Filter]) AND (english[Filter])))) Filters: English, Humans

**Embase:**

#1: 'amyotrophic lateral sclerosis'/exp/mj

#2: 'amyotrophic laterl sclerosis' OR 'als amyotrophic laterl sclerosis' OR 'als-amyotrophic laterl sclerosis' OR 'lou gehrig' OR 'motor neuron disease':ti,ab

#3: #1 OR #2

#4: 'clinical trial'/exp/mj

#5:'clinical trial' OR 'rct' OR 'open label' OR 'randomi\*':ti,ab

#6: #4 OR #5

#7: #3 AND #6

#8: #3 AND #6 AND [humans]/lim AND [english]/lim

|  |  |  |  |
| --- | --- | --- | --- |
| **Supplementary Table 1. Included documents after full-text reading** | | | |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Abe K, Aoki M, Tsuji S, et al. (2017) | Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial | Lancet neurol. | 16;(7):505-512 |
| Abe K, Itoyama Y, Aoki M, et al. (2017) | Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation) | Amyotrophic lateral sclerosis & frontotemporal degeneration | 18;40-48 |
| Abe K, Itoyama Y, Sobue G, et al. (2014) | Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients | Amyotrophic lateral sclerosis & frontotemporal degeneration | 15;(7):610-617 |
| Aggarwal SP, Zinman L, Simpson E, et al. (2010) | Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. | The lancet. Neurology | 9;(5):481-488 |
| Ahmadi M, Agah E, Nafissi S, et al. (2018) | Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial. | Neurotherapeutics: the journal of the american society for experimental neurotherapeutics | 15;(2):430-438 |
| Aisen ML, Sevilla D, Edelstein L and Blass J (1996) | A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit | J. Neurol. Sci. | 138;(1):93-96 |
| Aisen ML, Sevilla D, Gibson G, et al. (1995) | 3,4-diaminopyridine as a treatment for amyotrophic lateral sclerosis. | Journal of the neurological sciences | 129;(1):21-24 |
| Aizawa H., Kato H., Oba, K., et al. (2022) | Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis | J neurol | 269;(2):885-896 |
| Al-Chalabi A, Shaw P, Leigh PN, et al. (2019) | Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. | Journal of neurology, neurosurgery, and psychiatry | 90;(10):1165-1170 |
| ALS CNTF Treatment Study Group (1996) | A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. | Neurology | 46;(5):1244-1249 |
| Apostolski S, Marinkovic Z, Nikolic A, et al. (1998) | Glutathione Peroxidase in Amyotrophic Lateral Sclerosis: The Effects of Selenium Supplementation | Journal of environmental pathology, toxicology and oncology | 17;325-329 |
|  |  |  |  |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Appel SH, Stewart SS, Appel V et al. (1988) | A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. | Archives of neurology | 45;(4):381-386 |
| Aquilonius SM, Askmark H, Eckernas SA, et al. (1986) | Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine. | Acta neurol. Scand. | 73;(6):628-632 |
| Arriada-Mendicoa N, Otero-Siliceo E, Burbano G and Corona-Va¡zquez T (1999) | Open label study of riluzole for the treatment of amyotrophic lateral sclerosis | Rev. Ecuat. Neurol. | 8;(3):33-36 |
| Askmark H, Aquilonius SM, Gillberg PG (1993) | A pilot trial of dextromethorphan in amyotrophic lateral sclerosis | Jrournal of neurology, neurosurgery, and psychiatry | 56;197-200 |
| Askmark H, Aquilonius S-M, Gillberg P-G, et al. (1990) | Functional and pharmacokinetic stu tetrahydroaminoacridine in patients with amyotrophic lateral sclerosis | Acta neurol scand | 82;253-258 |
| Babu S, Macklin EA, Jackson KE, et al. (2020) | Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. | Amyotrophic lateral sclerosis & frontotemporal degeneration | 21;(1):15-23 |
| Beck M, Flachenecker P, Magnus T, et al. (2005) | Autonomic dysfunction in ALS: A preliminary study on the effects of intrathecal BDNF | Amyotrophic lateral scler. Other mot. Neuron disord. | 6;(2):100-103 |
| Bedlack RS, Wicks P, Vaughan T, et al. (2019) | Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial. | Amyotrophic lateral sclerosis & frontotemporal degeneration | 20;(3):285-293 |
| Beghi E, Chiò A, Inghilleri M, et al. (2000) | A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group. | Neurology | 54;(2):469-474 |
| Beghi E, Presti ML, Manzoni C, et al. (1996) | Ceftriaxone in amyotrophic lateral sclerosis | Eur. J. Neurol. | 3;(4):295-298 |
| Beghi E, Pupillo E, Bonito V, et al. (2013) | Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS | Amyotrophic lateral sclerosis & frontotemporal degeneration | 14;(5):397-405 |
| Benatar M, Wuu J, Andersen PM et al. (2018) | Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. | Neurology | 90;(7):e565-e574 |
| Bensimon G, Lacomblez L and Meininger V (1994) | A controlled trial of riluzole in amyotrophic lateral sclerosis | The new england journal of medicine | 330;(9):585-591 |
| Bensimon G, Lacomblez L, Delumeau JC et al. (2002) | A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis | J neurol | 249;609–615 |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Berto MC, Filha SC, Camelier A, et al. (2007) | Acute action of aminophylline in patients with amyotrophic lateral sclerosis | Acta neurol. Scand. | 115;(5):301-305 |
| Bertorini TE, Rashed H, Zeno M et al. (2011) | Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases | J. Clin. Neuromuscular dis. | 12;(3):129-137 |
| Blin O, Azulay JP, Desnuelle C, et al. (1996) | A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis | Clin. Neuropharmacol. | 19;(2):189-192 |
| Blin O, Pouget J, Aubrespy G, et al. (1992) | A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis. | Journal of neurology | 239;(2):79-81 |
| Boll M-C, Bayliss L, Vargas-Caas S, et al. (2014) | Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis | J. Neurol. Sci. | 340;(1):103-108 |
| Bonuccelli U, Nuti A, Rossi B, et al. (1990) | Thyroid function and oral TRH in amyotrophic lateral sclerosis | New trends clin. Neuropharmacol. | 4;(1):33-42 |
| Borasio GD, Robberecht W, Leigh PN, et al. (1998) | A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis | Neurology | 51;(2):583-586 |
| Bradley W.G. (1984) | Double-blind controlled trial of purified brain gangliosides in amyotrophic lateral sclerosis and experience with peripheral neuropathies. | Adv. Exp. Med. Biol. | 174;565-573 |
| Bradley WG, Hedlund W, Cooper C, et al. (1984) | A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. | Neurology | 34;(8):1079-1082 |
| Brody JA, Chen KM, Yase Y, et al. (1974) | Inosiplex and amyotrophic lateral sclerosis. Therapeutic trial in patients on Guam. | Archives of neurology | 30;(4):322-323 |
| Brooke MH, Florence JM, Heller SL, et al. (1986) | Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis. | Neurology | 36;(2):146-151 |
| Brooks BR, Sufit RL, Montgomery GK, et al. (1987) | Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies. | Neurologic clinics | 5;(1):143-158 |
| Brown RH Jr, Hauser SL, Harrington H, Weiner HL (1986) | Failure of Immunosuppression With a Ten- to 14-Day Course of High-Dose Intravenous Cyclophosphamide to Alter the Progression of Amyotrophic Lateral Sclerosis | Archives of neurology | 43;383-384 |
| Caroscio JT, Cohen JA, Zawodniak J, et al. (1986) | A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis. | Neurology | 36;(2):141-145 |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Chandrashekhar S, Hamasaki AC, Clay R, et al. (2022) | Open-label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis. | Muscle & nerve | 66;(1):71-75 |
| Chen P-C, Hsieh Y-C, Huang C-C and Hu C-J (2020) | Tamoxifen for amyotrophic lateral sclerosis: A randomized double-blind clinical trial | Medicine (baltimore) | 99;(22):e20423 |
| Chico L, Lo Gerfo A, Petrozzi L, et al. (2018) | Amyotrophic lateral sclerosis and oxidative stress: A doubleblind therapeutic trial after curcumin supplementation | Clin. Neuropathol. | 37;(3):117-118 |
| Chiò A, Borghero G, Calvo A, et al. (2010) | Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. | Neurology | 75;(7):619-625 |
| Chiò A, Cucatto A, Terreni AA and Schiffer D (1998) | Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial. | Italian journal of neurological sciences | 19;(6):363-366 |
| Clemens KE and Klaschik E (2008) | Morphine in the management of dyspnoea in ALS. A pilot study | Eur. J. Neurol. | 15;(5):445-450 |
| Congia S, Tronci S, Ledda Met al. (1991) | Low doses of TRH in amyotrophic lateral sclerosis and in other neurological diseases | Italian journal of neurological sciences | 12;(2):193-198 |
| Cudkowicz M, Bozik ME, Ingersoll EW, et al. (2011) | The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. | Nature medicine | 17;(12):1652-1656 |
| Cudkowicz M, Genge A, Maragakis N, et al. (2021) | Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet neurol. | 20;(10):821-831 |
| Cudkowicz ME, Andres PL, Macdonald SA, et al. (2009) | Phase 2 study of sodium phenylbutyrate in ALS. | Amyotrophic lateral sclerosis: official publication of the world federation of neurology research group on motor neuron diseases | 10;(2):99-106 |
| Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. (2003) | A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. | Neurology | 61;(4):456-464 |
| Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. (2006) | Trial of celecoxib in amyotrophic lateral sclerosis. | Annals of neurology | 60;(1):22-31 |
| Cudkowicz ME, Titus S, Kearney M, et al. (2014) | Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. | The lancet. Neurology | 13;(11):1083-1091 |
| Cudkowicz ME, van den Berg LH, Shefner JM, et al. (2013) | Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. | The lancet. Neurology | 12;(11):1059-1067 |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Dalakas MC, Aksamit AJ, Madden DL, Sever JL (1986) | Administration of Recombinant Human Leukocyte alpha2-Interferon in Patients with Amyotrophic Lateral Sclerosis | Archives of neurology | 43;933-935 |
| Dalakas MC, Stein DP, Otero C, et al. (1994) | Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy | Archives of neurology | 51;(9):861-864 |
| Dalla Bella E, Bersano E, Antonini G, et al. (2021) | The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. | Brain: a journal of neurology | 144;(9):2635-2647 |
| De Carvalho M, Pinto S, Costa J, et al. (2010) | A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis | Amyotrophic lateral scler. | 11;(5):456-460 |
| de Carvalho Silva LB, Mourao LF, Silva AA, et al. (2010) | Effect of nutritional supplementation with milk whey proteins in amyotrophic lateral sclerosis patients. | Arquivos de neuro-psiquiatria | 68;(2):263-268 |
| de la Rubia JE, Drehmer E, Platero JL, et al. (2019) | Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. | Amyotrophic lateral sclerosis & frontotemporal degeneration | 20;(1):115-122 |
| Debove C, Zeisser P, Salzman PM, et al. (2001) | The RilutekÂ® (riluzole) global early access programme: An open-label safety evaluation in the treatment of amyotrophic lateral sclerosis | Amyotrophic lateral scler. Other mot. Neuron disord. | 2;(3):153-158 |
| Desnuelle C, Dib M, Garrel C and Favier A (2001) | A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. | Amyotrophic lateral sclerosis: official publication of the world federation of neurology research group on motor neuron diseases | 2;(1):9-18 |
| Drory VE and Gross D (2002) | No effect of creatine on respiratory distress in amyotrophic lateral sclerosis | Amyotrophic lateral scler. Other mot. Neuron disord. | 3;(1):43-46 |
| Duning T, Schiffbauer H, Warnecke T, et al. (2011) | G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial. | Plos one | 6;(3):e17770 |
| Dupuis L, Dengler R, Heneka MT, et al. (2012) | A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. | Plos one | 7;(6):e37885 |
| Eisen A, Stewart H, Schulzer M and Cameron D (1993) | Anti-glutamate therapy in amyotrophic lateral sclerosis: A trial using lamotrigine | Can. J. Neurol. Sci. | 20;(4):297-301 |
| Elia AE, Lalli S, Monsurrò MR, et al. (2016) | Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis | Eur. J. Neurol. | 23;(1):45-52 |
| Fareed G.C. and Tyler, H.R. (1971) | The use of isoprinosine in patients with amyotrophic lateral sclerosis. | Neurology | 21;(9):937-940 |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Farkkila AM, Iivanainen MV and Farkkila MA (1990) | Disturbance of the water and electrolyte balance during high-dose interferon treatment. | Journal of interferon research | 10;(2):221-227 |
| Farkkila M, livanainen M, Roine R, et al. (1984) | Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis | Acta neurol scand | 69;42-46 |
| Fornai F, Longone P, Cafaro L, et al. (2008) | Lithium delays progression of amyotrophic lateral sclerosis | Pnas | 105;2052-2057 |
| Fournier CN, Schoenfeld D, Berry JD, et al. (2018) | An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. | Amyotrophic lateral sclerosis & frontotemporal degeneration | 19;(3):242-249 |
| Gordon PH, Cheung YK, Levin B, et al. (2008) | A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. | Amyotrophic lateral sclerosis: official publication of the world federation of neurology research group on motor neuron diseases | 9;(4):212-222 |
| Gordon PH, Moore DH, Miller RG, et al. (2007) | Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. | The lancet. Neurology | 6;(12):1045-1053 |
| Gordon, Doorish C, Montes J, et al. (2006) | Randomized controlled phase II trial of glatiramer acetate in ALS | Neurology | 66;(7):1117-1119 |
| Gourie-Devi M, Nalini A and Subbakrishna DK (1997) | Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis | J. Neurol. Sci. | 150;(2):167-172 |
| Graf M, Ecker D, Horowski R, et al. (2005) | High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. | Journal of neural transmission | 112;(5):649-660 |
| Gredal O, Werdelin L, Bak S et al. (1997) | A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. | Acta neurol. Scand. | 96;(1):8-13 |
| Groeneveld GJ, Beijer C, Veldink JH, et al. (2005) | Few adverse effects of long-term creatine supplementation in a placebo-controlled trial | Int. J. Sports med. | 26;(4):307-313 |
| Groeneveld GJ, Veldink JH, Van der Tweel I, et al. (2003) | A randomized sequential trial of creatine in amyotrophic lateral sclerosis | Annals of neurology | 53;(4):437-445 |
| Guiloff RJ, Eckland DJ, Demaine C, et al. (1987) | Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease. | Journal of neurology, neurosurgery, and psychiatry | 50;(10):1359-1370 |
| Harrington H, Hallett M and Tyler HR (1984) | Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial. | Neurology | 34;(8):1083-1085 |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Hawley RJ, Kratz R, Goodman RR, et al. (1987) | Treatment of amyotrophic lateral sclerosis with the TRH analog DN-1417. | Neurology | 37;(4):715-717 |
| Hesselmans LFGM, Wieneke GH, Oey PL, et al. (1993) | Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease | Neuromuscular disord. | 3;(4):319-325 |
| Hotait M, Ismail HH, Saab GE and Salameh JS (2021) | An open label pilot study of the safety and tolerability of perampanel in amyotrophic lateral sclerosis | Muscle & nerve | 64;(4):504-508 |
| Imoto K, Saida K, Iwamura K, et al. (1984) | Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone. | Journal of neurology, neurosurgery, and psychiatry | 47;(12):1332-1334 |
| Jones TM, Yu R, Antel JP (1982) | Response of Patients With Amyotrophic Lateral Sclerosis to Testosterone Therapy | Archives of neurology | 39;721-722 |
| Jossan SS, Ekblom J, Gudjonsson O, et al. (1994) | Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis | J. Neural transm. | SUPPL.;(41):237-241 |
| Juntas-Morales R, Pageot N, Bendarraz A, et al. (2020) | High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study | Eclinicalmedicine | 19 |
| Kaji R, Imai T, Iwasaki Y, et al. (2019) | Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: A long-term phase II/III randomised controlled study | Journal of neurology, neurosurgery, and psychiatry | 90;(4):451-457 |
| Kaji R, Kodama M, Imamura A (1998) | Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double-blind controlled study | Muscle & nerve | 21;(12):1775-1778 |
| Kalra S, Genge A and Arnold DL (2003) | A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: Feasibility and results | Amyotrophic lateral scler. Other mot. Neuron disord. | 4;(1):22-26 |
| Kaufmann P, Thompson JLP, Levy G, et al. (2009) - study N 2 | Phase II Trial of CoQ10 for ALS Finds Insufficient Evidence to Justify Phase III | Ann neurol | 66;235-244 |
| Kaufmann P, Thompson JLP, Levy G, et al. (2009) - study N 1 | Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III | Annals of neurology | 66;(2):235-244 |
| Kelemen J, Hedlund W, Murray-Douglass P, et al. (1982) | Lecithin is not effective in amyotrophic lateral sclerosis | Neurology | 32;315-316 |
|  |  |  |  |
|  |  |  |  |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Kindy M, Lupinacci P, Chau R, et al. (2017) | A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C) | F1000 res. | 6 |
| Kovalchuk MO, Heuberger JAAC, Sleutjes BTHM, et al. (2018) | Acute Effects of Riluzole and Retigabine on Axonal Excitability in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. | Clinical pharmacology and therapeutics | 104;(6):1136-1145 |
| Lacomblez L, Bensimon G, Douillet P, et al. (2004) | Xaliproden in amyotrophic lateral sclerosis: Early clinical trials | Amyotrophic lateral scler. Other mot. Neuron disord. | 5;(2):99-106 |
| Lacomblez L, Bensimon G, Leigh PN, et al. (1996) | Dose-ranging study of riluzole in amyotrophic lateral sclerosis | Lancet | 347;(9013):1425-1431 |
| Lacomblez L, Bensimon G, Leigh PN, et al. (1996) | Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. | Lancet (london, england) | 347;(9013):1425-1431 |
| Lacomblez L, Bouche P, Bensimon G and Meininger V (1989) | A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. | Neurology | 39;(12):1635-1637 |
| Lai EC, Felice KJ, Festoff BW, et al. (1997) | Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. | Neurology | 49;(6):1621-1630 |
| Lange DJ, Felice KJ, Festoff BW, et al. (1996) | Recombinant human insulin-like growth factor-I in ALS: Description of a double-blind, placebo-controlled study | Neurology | 47;(4):S93-S95 |
| Lange DJ, Murphy PL, Diamond B, et al. (1998) | Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. | Archives of neurology | 55;(1):93-96 |
| Lauria G, Campanella A, Filippini G, et al. (2009) | Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. | Amyotrophic lateral sclerosis: official publication of the world federation of neurology research group on motor neuron diseases | 10;(5):410-415 |
| Lauria G, Dalla Bella E, Antonini G, et al. (2015) | Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. | Journal of neurology, neurosurgery, and psychiatry | 86;(8):879-886 |
| Lazzarino G, Mangione R, Belli A, et al. (2021) | IlbÂ® attenuates clinical symptoms and serum biomarkers of oxidative/nitrosative stress and mitochondrial dysfunction in patients with amyotrophic lateral sclerosis | J. Pers. Med. | 11;(8) |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Lenglet T, Lacomblez L, Abitbol JL, et al. (2014) | A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis | Eur. J. Neurol. | 21;(3):529-536 |
| Levine TD, Bowser R, Hank N and Saperstein D (2010) | A pilot trial of memantine and riluzole in ALS: Correlation to CSF biomarkers | Amyotrophic lateral scler. | 11;(6):514-519 |
| livanainenl M, Laaksonen R, Niemi ML, et al. (1985) | Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis | Acta neurol scand | 72;475-48 |
| Logan A, Nagy Z, Barnes NM, et al. (2022) | A phase II open label clinical study of the safety, tolerability and efficacy of ILBÂ® for Amyotrophic Lateral Sclerosis. | Plos one | 17;(5):e0267183 |
| Louwerse ES, Weverling GJ, Bossuyt PMM, et al. (1995) | Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis | Archives of neurology | 52;(6):559-564 |
| Ludolph AC, Schuster J, Dorst J, et al. (2018) | Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. | The lancet. Neurology | 17;(8):681-688 |
| Macchi Z, Wang Y, Moore D, et al. (2015) | A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement | Amyotrophic lateral sclerosis & frontotemporal degeneration | 16;(5):345-352 |
| Maier A, Deigendesch N, Muller K, et al. (2015) | Interleukin-1 antagonist Anakinra in amyotrophic lateral sclerosis - A pilot study | Plos one | 10;(10) |
| Mazzini L, Mora G, Balzarini C, et al. (1998) | The natural history and the effects of gabapentin in amyotrophic lateral sclerosis | J. Neurol. Sci. | 160;S57-S63 |
| Mazzini L, Testa D, Balzarini C and Mora G (1994) | An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis | J neurol | 241;(4):223-227 |
| Meininger V, Asselain B, Guillet P, et al. (2006) | Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. | Neurology | 66;(1):88-92 |
| Meininger V, Bensimon G, Bradley WR, et al. (2004) - study N 1 | Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. | Amyotrophic lateral sclerosis: official publication of the world federation of neurology research group on motor neuron diseases | 5;(2):107-117 |
|  |  |  |  |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Meininger V, Bensimon G, Bradley WR, et al. (2004) - study N 2 | Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. | Amyotrophic lateral sclerosis: official publication of the world federation of neurology research group on motor neuron diseases | 5;(2):107-117 |
| Meininger V, Drory VE, Leigh PN, et al. (2009) | Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. | Amyotrophic lateral sclerosis: official publication of the world federation of neurology research group on motor neuron diseases | 10;(5):378-383 |
| Meininger V, Genge A, van den Berg LH, et al. (2017) | Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. | The lancet. Neurology | 16;(3):208-216 |
| Meininger V, Pradat PF, Corse A, et al. (2014) - study N 1 | Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial. | Plos one | 9;(5):e97803 |
| Meininger V, Pradat PF, Corse A, et al. (2014) - study N 2 | Insufficient Evidence to Justify Phase III | Plos one | 9;(5):e97803 |
| Meucci N, Nobile-Orazio E and Scarlato G (1996) | Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis | J neurol | 243;(2):117-120 |
| Meyer T, Maier A, Borisow N, et al. (2008) | Thalidomide causes sinus bradycardia in ALS | J neurol | 255;(4):587-591 |
| Miller R, Bradley W, Cudkowicz M, et al. (2007) | Phase II/III randomized trial of TCH346 in patients with ALS | Neurology | 69;(8):776-784 |
| Miller RG, Block G, Katz JS, et al. (2015) | Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS | Neurol. Neuroimmunol. Neuroinflamm. | 2;(3):e100 |
| Miller RG, Moore D, Young LA, et al. (1996) | Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. | Neurology | 47;(6):1383-1388 |
| Miller RG, Moore DH, Forshew DA, et al. (2011) | Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: Examining a more efficient trial design | Neurology | 77;(10):973-979 |
| Miller RG, Moore II DH, Gelinas DF, et al. (2001) | Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis | Neurology | 56;(7):843-848 |
|  |  |  |  |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Miller RG, Petajan JH, Bryan WW, et al. (1996) | A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis | Annals of neurology | 39;(2):256-260 |
| Miller RG, Shepherd R, Dao H et al. (1996) | Controlled trial of nimodipine in amyotrophic lateral sclerosis | Neuromuscular disord. | 6;(2):101-104 |
| Miller RG, Smith SA, Murphy JR, et al. (1996) | A clinical trial of verapamil in amyotrophic lateral sclerosis. | Muscle & nerve | 19;(4):511-515 |
| Miller RG, Zhang R, Bracci PM, et al. (2022) | Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses | Muscle & nerve | 66;(1):39-49 |
| Miller T, Cudkowicz M, Shaw PJ, et al. (2020) | Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS | The new england journal of medicine | 383;(2):109-119 |
| Miller TM, Cudkowicz ME, Genge A, et al. (2022) | Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. | The new england journal of medicine | 387;(12):1099-1110 |
| Milligan C., Atassi N., Babu S., et al. (2021) | Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients | Muscle & nerve | 64;(3):309-320 |
| Min J-H, Hong Y-H, Sung J-J, et al. (2012) | Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: A randomized cross-over trial | J. Korean med. Sci. | 27;(2):200-206 |
| Mingsheng Liu, Xiaoli Yao, Xusheng Huang, et al. (2021) | A Randomized, Double-blind, Placebo-controlled Trial of DL-3-n-butylphthalide in Amyotrophic Lateral Sclerosis Patients | Research square |  |
| Mitsumoto H, Salgado ED, Negroski D, et al. (1986) - study N 1 | Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. | Neurology | 36;(2):152-159 |
| Mitsumoto H, Salgado ED, Negroski D, et al. (1986) - study N 2 | Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. | Neurology | 36;(2):152-159 |
| Modarres-Sadeghi H, Rogers H, Emami J and Guiloff RJ (1988) | Subacute administration of a TRH analogue (RX77368) in motorneuron disease: An open study | Journal of neurology, neurosurgery, and psychiatry | 51;(9):1146-1157 |
| Mora JS, Genge A, Chio A, et al. (2020) | Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. | Amyotrophic lateral sclerosis & frontotemporal degeneration | 21;(1):1-9 |
| Moreau C, Danel V, Devedjian JC, et al. (2018) | Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? | Antioxidants & redox signaling | 29;(8):742-748 |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Morimoto S, Takahashi S, Ito D, et al. (2021) | Ropinirole hydrochloride for amyotrophic lateral sclerosis: A single-center, randomized feasibility, double-blind, placebo-controlled trial | Medrxiv |  |
| Morrison KE, Dhariwal S, Hornabrook R, et al. (2013) | Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. | The lancet. Neurology | 12;(4):339-345 |
| Munsat TL, Easterday CS, Levy S, et al. (1981) | Amantadine and guanidine are ineffective in ALS. | Neurology | 31;(8):1054-1055 |
| Munsat TL, Taft J, Jackson I, et al. (1992) | Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: Experience with an intrathecal drug delivery system | Neurology | 42;(5):1049-1053 |
| Nagano I, Shiote M, Murakami T, et al. (2005) | Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. | Neurological research | 27;(7):768-772 |
| Nagata E, Ogino M, Iwamoto K, et al. (2016) | Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients. | Plos one | 11;(2):e0149509 |
| Nefussy B, Artamonov I, Deutsch V, et al. (2010) | Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study | Amyotrophic lateral scler. | 11;(1):187-193 |
| Nicholson K, Chan J, Macklin EA, et al. (2018) | Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis | Ann. Clin. Transl. Neurol. | 5;(12):1522-1533 |
| Norris FH, Denys EH and Fallat RJ (1986) | Trial of octacosanol in amyotrophic lateral sclerosis. | Neurology | 36;(9):1263-1264 |
| Norris FH, Tan Y, Fallat RJ and Elias L (1993) | Trial of oral physostigmine in amyotrophic lateral sclerosis | Clin. Pharmacol. Ther. | 54;(6):680-682 |
| Norris FHJ, Sang KU, Sachais B, Carey M (1979) | Trial of Baclofen in Amyotrophic Lateral Sclerosis | Archives of neurology | 36;715-716 |
| Norris Jr. F.H., Calanchini P.R. and Fallat R.J. (1974) | The administration of guanidine in amyotrophic lateral sclerosis | Neurology | 24;(8):721-728 |
| Oki R, Izumi Y, Fujita K, et al. (2022) | Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. | Jama neurology | 79;(6):575-583 |
| Olarte MR, Gersten JC, Zabriskie J, et al. (1979) | Transfer Factor Is Ineffective in Amyotrophic Lateral Sclerosis | Ann neurol | 5;385-388 |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Olarte MR, Shafer SQ (1985) | Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis | Neurology | 35;1063-1066 |
| Olson WH, Simons JA and Halaas GW (1978) | Therapeutic trial of tilorone in ALS: lack of benefit in a double-blind, placebo-controlled study. | Neurology | 28;(12):1293-1295 |
| Paganoni S, Macklin EA, Hendrix S, et al. (2020) | Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. | The new england journal of medicine | 383;(10):919-930 |
| Pan W, Su X, Bao J, et al. (2013) | Open randomized clinical trial on jwsjz decoction for the treatment of als patients | Evid.-based complement. Altern. Med. | 2013 |
| Park SB, Vucic S, Cheah BC, et al. (2015) | Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial | Ebiomedicine | 2;(12):1916-1922 |
| Pascuzzi RM, Shefner J, Chappell AS, et al. (2010) | A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis | Amyotrophic lateral scler. | 11;(3):266-271 |
| Patten SA, Aggad D, Martinez J, et al. (2017) | Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis | Jci insight | 22;(2):e97152 |
| Piepers S, Veldink JH, de Jong SW, et al. (2009) | Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. | Annals of neurology | 66;(2):227-234 |
| Plaitakis A, Smith J, Mandeli J and Yahr (1988) | Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. | Lancet (london, england) | 1;(8593):1015-1018 |
| Pontieri FE, Ricci A, Pellicano C et al. (2005) | Minocycline in amyotrophic lateral sclerosis: A pilot study | Neurol. Sci. | 26;(4):285-287 |
| Riva N, Mora G, Sorarù G, et al. (2019) | Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial | Lancet neurol. | 18;(2):155-164 |
| Rivera VM, Grabois M, Deaton W, et al. (1980) | Modified Snake Venom in Amyotrophic Lateral Sclerosis Lack of Clinical Effectiveness | Archives of neurology | 37;201-203 |
| Rosenfeld J, King RM, Jackson CE, et al. (2008) | Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS | Amyotrophic lateral scler. | 9;(5):266-272 |
| Ryberg H, Askmark H, Persson LI (2003) | A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. | Acta neurol. Scand. | 108;(1):1-8 |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Saccà F, Quarantelli M, Rinaldi C, et al. (2012) | A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: Clinical, neuroimaging, and hormonal results | J neurol | 259;(1):132-138 |
| Salomon-Zimri S, Pushett A, Russek-Blum N, et al. (2022) | Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS | Amyotrophic lateral sclerosis & frontotemporal degeneration | 263-271 |
| Samadhiya S, Sardana V, Bhushan B, et al. (2022) | Assessment of therapeutic response of edaravone and riluzole combination therapy in amyotrophic lateral sclerosis patients | Ann. Indian acad. Neurol. | 25;(4):692-697 |
| Scelsa SN, MacGowan DJ, Mitsumoto H, et al. (2005) | A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. | Neurology | 64;(7):1298-1300 |
| Schiffman PL and Belsh JM (1989) | Effect of Inspiratory Resistance and Theophylline on Respiratory Muscle Strength in Patients with Amyotrophic Lateral Sclerosis | Am rev respir dis | 139;1418-1423 |
| Schroder S, Wang M, Sima D, et al. (2022) | Slower progression of amyotrophic lateral sclerosis with external application of a Chinese herbal plasterâ€“The randomized, placebo-controlled triple-blinded ALS-CHEPLA trial | Front. Neurol. | 13 |
| Shefner J, Cedarbaum JM, Cudkowicz ME, et al. (2012) | Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis | Amyotrophic lateral scler | 13;430-438 |
| Shefner JM, Andrews JA, Genge A, et al. (2021) | A Phase 2, Double-Blind, Randomized, DoseRanging Trial Of Reldesemtiv In Patients With ALS | Amyotrophic lateral sclerosis & frontotemporal degeneration | 22;(3-4):287-299 |
| Shefner JM, Cudkowicz ME, Hardiman O, et al. (2019) | A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis | Amyotrophic lateral sclerosis & frontotemporal degeneration | 20;(7):584-594 |
| Shefner JM, Cudkowicz ME, Schoenfeld D, et al. (2004) | A clinical trial of creatine in ALS. | Neurology | 63;(9):1656-1661 |
| Shefner JM, Watson ML, Meng L, et al. (2013) - study N 1 | A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis | Amyotrophic lateral sclerosis & frontotemporal degeneration | 14;574–581 |
| Shefner JM, Watson ML, Meng L, et al. (2013) -study N 2 | A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis | Amyotrophic lateral sclerosis & frontotemporal degeneration | 14;574–581 |
| Shefner JM, Wolff AA, Meng L, et al. (2016) | A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. | Amyotrophic lateral sclerosis & frontotemporal degeneration | 17;(5):426-435 |
|  |  |  |  |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| Shibuya K, Misawa S, Kimura H, et al. (2015) | A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial. | Amyotrophic lateral sclerosis & frontotemporal degeneration | 16;(5):353-358 |
| Smith R, Pioro E, Myers K, et al. (2017) | Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial | Neurotherapeutics | 14;(3):762-772 |
| Smith RA, Melmed S, Sherman B et al. (1993) | Recombinant growth hormone treatment of amyotrophic lateral sclerosis | Muscle & nerve | 16;(6):624-633 |
| Smith SA, Miller RG, Murphy JR and Ringel SP (1994) | Treatment of ALS with high dose pulse cyclophosphamide | J. Neurol. Sci. | 124;84-87 |
| Sommer M, Tergau F, Wischer S (1999) | Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis | J neurol | 246;III/22–III/26 |
| Sorarù G, Pegoraro E, Spinella P, et al. (2006) | A pilot trial with clenbuterol in amyotrophic lateral sclerosis | Amyotrophic lateral scler. | 7;(4):252-254 |
| Sorenson EJ, Windbank AJ, Mandrekar JN, et al. (2008) | Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. | Neurology | 71;(22):1770-1775 |
| Statland JM, Moore D, Wang Y, et al. (2019) | Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. | Muscle & nerve | 59;(2):201-207 |
| Stober T, Schimrigk K, Dietzsch S and T. Thielen (1985) | Intrathecal thyrotropin-releasing hormone therapy of amyotrophic lateral sclerosis | J neurol | 232;13-14 |
| Stommel EW, Cohen JA, Fadul CE, et al. (2009) | Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial | Amyotrophic lateral scler. | 10;(5):393-404 |
| Tan E, Lynn DJ, Amato AA (1994) | Immunosuppressive Treatment of Motor Neuron Syndromes | Archives of neurology | 51;194-200 |
| Tandan R, Bromberg MB, Forshew D, et al. (1996) | A controlled trial of amine acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data | Neurology | 47;(5):1220-1226 |
| Testa D, Caraceni T and Fetoni V (1989) | Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis | J neurol | 236;445-447 |
| Testa D, Caraceni T, Fetoni V and Girotti F (1992) | Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study. | Clinical neurology and neurosurgery | 94;(1):7-9 |
|  |  |  |  |
| **Author (year)** | **Title** | **Journal** | **Reference** |
| The BDNF study group (1999) | A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). | Neurology | 52;(7):1427-1433 |
| The Italian ALS Study Group (1993) | Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? The Italian ALS Study Group. | Neurology | 43;(12):2466-2470 |
| Trojsi F, Siciliano M, Passaniti C, et al. (2020) | Vitamin D supplementation has no effects on progression of motor dysfunction in amyotrophic lateral sclerosis (ALS). | European journal of clinical nutrition | 74;(1):167-175 |
| Tyler HR (1979) | Double-blind study of modified neurotoxin in motor neuron disease. | Neurology | 29;(1):77-81 |
| Van Es MA, Van Eijk RPA, Bunte TM and Van Den Berg LH (2020) | A placebo-controlled trial to investigate the safety and efficacy of Penicillin G/Hydrocortisone in patients with ALS (PHALS trial). | Amyotrophic lateral sclerosis & frontotemporal degeneration | 21;(7):584-592 |
| Verstraete E, Veldink JH, Huisman MHB, et al. (2012) | Lithium lacks effect on survival in amyotrophic lateral sclerosis: A phase IIb randomised sequential trial | Journal of neurology, neurosurgery, and psychiatry | 83;(5):557-564 |
| Vucic S, Henderson RD, Mathers S, et al. (2021) | Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study | Ann. Clin. Transl. Neurol. | 8;(10):1991-1999 |
| Wainger BJ, Macklin EA, Vucic S, et al. (2021) | Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. | Jama neurology | 78;(2):186-196 |
| Wang H, Larriviere KS, Keller KE, et al. (2008) | R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. | Amyotrophic lateral sclerosis: official publication of the world federation of neurology research group on motor neuron diseases | 9;(1):50-58 |
| Weiss MD, Macklin EA, McIlduff CE, et al. (2021) | Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial | Muscle & nerve | 63;(3):371-383 |
| Weiss MD, Macklin EA, Simmons Z, et al. (2016) | A randomized trial of mexiletine in ALS | Neurology | 86;(16):1474-1481 |
| Yoshino H and Kimura A (2006) | Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study) | Amyotrophic lateral scler. | 7;(4):247-251 |
| Zhang Y, Wang L, Fu Y, et al. (2009) | Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis | Amyotrophic lateral scler. | 10;430-431 |
| Ziv I, Achiron A, Djaldetti R, et al. (1994) | Can nimodipine affect progression of motor neuron disease? A double-blind pilot study | Clin. Neuropharmacol. | 17;(5):423-428 |

**Supplementary table 2: List of excluded documents after full text reading**

|  |  |  |  |
| --- | --- | --- | --- |
| **Author (year)** | **Title** | **Reference** | **Reason for Exclusion** |
| Berry JD, Cudkowicz ME, Windebank AJ, et al. (2019) | NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results | Neurology 10;93(24):e2294-e2305 | wrong drug |
| Cashman N, Tan LY, Krieger C, et al. (2008) | Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS) | Muscle Nerve 37(5):620-5 | wrong drug |
| Chiò A, Mora G, La Bella V, et al. (2011) | Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study | Muscle Nerve 43(2):189-95 | wrong drug |
| Berry JD, Paganoni S, Atassi N, et al. (2017) | Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability | Muscle Nerve 56(6):1077-84 | wrong outcome |
| Conradi S, Ronnevi LO, Nise G, et al. (1982) | Long-time penicillamine-treatment in amyotrophic lateral sclerosis with parallel determination of lead in blood, plasma and urine | Acta Neurol Scand 65(3):203-11 | wrong outcome |
| Cudkowicz ME, Shefner JM, Simpson E, et al. (2008) | Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis | Muscle Nerve 38(1):837-44 | wrong outcome |
| Ferrante KL, Shefner J, Zhang H, et al. (2005) | Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS | Neurology 65(11):1834-6 | wrong outcome |
| Lacomblez L, Bensimon G, Leigh PN, et al. (2002) | Long-term safety of riluzole in amyotrophic lateral sclerosis | Amyotroph Lateral Scler Other Motor Neuron Disord 3(1):23-9 | wrong outcome |
| Lange DJ, Shahbazi M, Silani V, et al. (2017) | Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations | Ann Neurol 81(6):837-84 | wrong outcome |
| Ochs G, Penn RD, York M, et al. (2000) | A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis | Amyotroph Lateral Scler Other Motor Neuron Disord 1(3):201-6 | wrong outcome |
| Parry GJ, Rodrigues CM, Aranha MM, et al. (2010) | Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis | Clin Neuropharmacol 33(1):17-21 | wrong outcome |
| Pongratz D, Neundörfer B, Fischer W (2000) | German open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS) | J Neurol Sci 180(1-2):82-5 | wrong outcome |
| **Author (year)** | **Title** | **Reference** | **Reason for Exclusion** |
| Poutiainen E, Hokkanen L, Niemi ML, et al. (1994) | Reversible cognitive decline during high-dose alpha-interferon treatment | Pharmacol Biochem Behav 47(4): 901-5 | wrong outcome |
| Desai J, Sharief M, Swash M (1998) | Riluzole has no acute effect on motor unit parameters in ALS | J Neurol Sci 160 Suppl 1:S69-72 | wrong population |
| Goonetilleke A, Guiloff RJ (1995) | Continuous response variable trial design in motor neuron disease: long term treatment with a TRH analogue (RX77368) | J Neurol Neurosurg Psychiatry 58(2):201-8 | wrong population |
| Lipp A, Trottenberg T, Schink T, Kupsch A, et al. (2003) | A randomized trial of botulinum toxin A for treatment of drooling | Neurology 61(9):1279-81 | wrong population |
| Panitch HS, Thisted RA, Smith RA, et al. (2006) | Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis | Ann Neurol 59(5):780-7 | wrong population |
| Porta M, Gamba M, Bertacchi G, et al. (2001) | Treatment of sialorrhea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders | J Neurol Neurosurg Psychiatry 70(4):538-40 | wrong population |
| Vázquez-Costa JF, Máñez I, Alabajos A, et al. (2016) | Safety and efficacy of botulinum toxin A for the treatment of spasticity in amyotrophic lateral sclerosis: results of a pilot study | J Neurol 263(10):1954-60 | wrong population |
| Gordon PH, Moore DH, Gelinas DF, et al. (2004) | Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis | Neurology 62(10):1845-7 | wrong publication type |
| Johannesen S, Bogdahn U, Bruun T-H, et al. (2021) | Modeling and bioinformatics identify responders to G-CSF in patients with amyotrophic lateral sclerosis | J Neurol Sci 429 Article N° 119395 Suppl | wrong publication type |
| Verma A, Steele J (2006) | Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis | Muscle Nerve 34(2):235-7 | wrong publication type |
| Blasco H, Patin F, Descat A, et al. (2018) | A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression | PLoS One 13(6):e0198116 | wrong study type |
| Camu W, Mickunas M, Veyrune JL, et al. (2020) | Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial | EBioMedicine 59:102844 | wrong study type |
| Desiato MT, Palmieri MG, Giacomini P, et al. (1999) | The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation | J Neurol Sci 169(1-2):98-107 | wrong study type |
| Engel WK, Siddique T, Nicoloff JT (1983) | Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone | Lancet 2(8341):73-5 | wrong study type |
| **Author (year)** | **Title** | **Reference** | **Reason for Exclusion** |
| Gold J, Rowe DB, Kiernan MC, et al. (2019) | Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial | Amyotroph Lateral Scler Frontotemporal Degener 20(7-8):595-604 | wrong study type |
| Nagase M, Yamamoto Y, Miyazaki Y, et al. (2016) | Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration | Redox Rep 21(3):104-12 | wrong study type |
| Park JM, Kim SY, Park D, et al. (2020) | Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients | Neurol Sci 41(1):119-123 | wrong study type |
| Restivo DA, Casabona A, Nicotra A, et al. (2013) | ALS dysphagia pathophysiology: differential botulinum toxin response | Neurology 2013 80(7):616-20 | wrong study type |
| Sojka P, Andersen PM, Forsgren L (1997) | Effects of riluzole on symptom progression in amyotrophic lateral sclerosis | Lancet 349(9046):176-7 | wrong study type |
| Sufit RL, Ajroud-Driss S, Casey P, et al. (2017) | Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis | Amyotroph Lateral Scler Frontotemporal Degener 18(3-4):269-278 | wrong study type |
| Wong C, Dakin RS, Williamson J, et al. (2022) | Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease | BMJ Open 12(7):e064173 | wrong study type |
| Yamane K, Osawa M, Kobayashi I, et al. (1986) | Treatment of amyotrophic lateral sclerosis with thyrotropin-releasing hormone (TRH) | Jpn J Psychiatry Neurol 40(2):179-87 | wrong study type |
| Paracka L, Kollewe K, Klietz M, et al. (2019) | IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study | J Neural Transm (Vienna) 126(10):1341-5 | wrong study type |
| Weishaupt JH, Bartels C, Pölking E, et al. (2006) | Reduced oxidative damage in ALS by high-dose enteral melatonin treatment | J Pineal Res 41(4):313-23 | wrong study type |

**Supplementary Table N3. Drug name and number of studies** **with positive or negative results**

|  |  |  |  |
| --- | --- | --- | --- |
| **Drug Name** | **N positive results** | **N negative results** | **Total** |
| **3,4 - DIAMMINOPIRIDINA (DAP)** | 2 | 1 | 3 |
| **4-IMMUNOSUPPRESSIVE DRUG REGIMEN** | 0 | 1 | 1 |
| **9-AMMINO- 1,2,3,4-TETRAIDROACRIDINA (THA)** | 0 | 1 | 1 |
| **ACETILCISTEINE** | 0 | 1 | 1 |
| **ACETYL-L-CARNITINE** | 1 | 0 | 1 |
| **ALPHA-TOCOPHEROL (Vit E)** | 0 | 2 | 2 |
| **AMINOPHYLLINE** | 1 | 0 | 1 |
| **ANAKINRA** | 0 | 1 | 1 |
| **ARIMOCLOMOL** | 1 | 0 | 1 |
| **BACLOFEN** | 0 | 1 | 1 |
| **BDNF** | 0 | 2 | 2 |
| **BIOTINE (MD1003)** | 1 | 0 | 1 |
| **BRAINOIL** | 1 | 0 | 1 |
| **BRANCHED-CHAIN AMINO ACIDS** | 1 | 3 | 4 |
| **BROMCRIPTINA** | 1 | 0 | 1 |
| **CEFTRIAXONE** | 0 | 2 | 2 |
| **CELECOXIB** | 0 | 1 | 1 |
| **CELECOXIB + CIPROFLOXACIN** | 1 | 0 | 1 |
| **CICLOFOSFAMIDE** | 1 | 1 | 2 |
| **CK-2017357** | 1 | 0 | 1 |
| **CLENBUTEROL** | 1 | 0 | 1 |
| **COLECALCIFEROLO** | 0 | 1 | 1 |
| **COQ10** | 0 | 2 | 2 |
| **CORTICOTROPINA + CICLOFOSFAMIDE** | 0 | 1 | 1 |
| **CREATINE** | 1 | 4 | 5 |
| **CYCLOSPORINE** | 0 | 1 | 1 |
| **DEFERIPRONE** | 0 | 1 | 1 |
| **DELTA-9-TETRAHYDROCANNABINOL + CANNABIDIOL** | 1 | 0 | 1 |
| **DESTRAN SOLFATO** | 2 | 0 | 2 |
| **DESTROMETORFANO** | 0 | 3 | 3 |
| **DEXPRAMIPEXOLE** | 1 | 1 | 2 |
| **DIMETHYLFUMARATE** | 0 | 1 | 1 |
| **DL-3-N-BUTYLPHTIALIDE (NBP)** | 0 | 1 | 1 |
| **DN-1417** | 0 | 1 | 1 |
| **EDARAVONE** | 3 | 2 | 5 |
| **ELYSIUM HEALTH’S CANDIDATE DRUG EH301** | 1 | 0 | 1 |
| **ERITROPOIETINA UMANA RICOMBINANTE (RHEPO)** | 1 | 1 | 2 |
| **EZOGABINE** | 1 | 0 | 1 |
| **FISOSTIGMINA** | 0 | 1 | 1 |
| **FLECAINIDE** | 0 | 1 | 1 |
| **GABAPENTIN** | 1 | 2 | 3 |
| **GANGLIOSIDI** | 0 | 4 | 4 |
| **GLATIRAMER ACETATE** | 1 | 1 | 2 |
| **GLUTATHIONE PEROXIDASE** | 1 | 0 | 1 |
| **GLUTATIONE RIDOTTO (GSH)** | 0 | 1 | 1 |
| **GM604** | 0 | 1 | 1 |
| **GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF)** | 1 | 2 | 3 |
| **GROWTH HORMON** | 0 | 1 | 1 |
| **GUANABENZ** | 1 | 0 | 1 |
| **GUANIDINE** | 1 | 0 | 1 |
| **GUANIDINE O AMANTDINE** | 0 | 1 | 1 |
| **HUMAN LEUCOCYTE INTERFERON (IFN)** | 0 | 3 | 3 |
| **IFNB-1A** | 0 | 1 | 1 |
| **IMMUNOGLOBULINE** | 0 | 2 | 2 |
| **INDINAVIR** | 0 | 1 | 1 |
| **INOSINE** | 1 | 0 | 1 |
| **INOSITOLE (Vit B7)** | 0 | 1 | 1 |
| **INSULIN-LIKE GROWTH FACTOR-1 (IGF-1)** | 1 | 1 | 2 |
| **ISOPRINOSINA** | 0 | 1 | 1 |
| **JI WU LI** | 1 | 0 | 1 |
| **JWSJZ DECOCTION** | 0 | 1 | 1 |
| **LAMOTRIGINE** | 0 | 2 | 2 |
| **L-DEPRENYL** | 0 | 1 | 1 |
| **LECITINE** | 0 | 1 | 1 |
| **LEVAMISOLE** | 0 | 1 | 1 |
| **LEVOSIMENDAN** | 0 | 2 | 2 |
| **LITHIUM CARBONATE** | 1 | 5 | 6 |
| **LITHIUM CARBONATE + VALPROIC ACID** | 1 | 0 | 1 |
| **L-TREONINA** | 0 | 2 | 2 |
| **LUNASIN** | 0 | 1 | 1 |
| **MASITINIB** | 1 | 0 | 1 |
| **MEMANTINE** | 1 | 1 | 2 |
| **METILCOBALAMINA** | 2 | 1 | 3 |
| **METILPREDNISOLONE + PREDNISONE; THAN CICLOFOSFAMIDE** | 0 | 1 | 1 |
| **MEXILETINE** | 2 | 1 | 3 |
| **MILK WHEY PROTEINS** | 0 | 1 | 1 |
| **MINOCICLINA** | 1 | 1 | 2 |
| **MINOCICLINA + CREATINA (MC) E CELECOXIB + CREATINA (CC)** | 1 | 0 | 1 |
| **MODIFIED NEUROTOXIN** | 0 | 1 | 1 |
| **MODIFIED VENOM SNAKE** | 0 | 1 | 1 |
| **MORFINA** | 1 | 0 | 1 |
| **NANOCURCUMINA** | 1 | 0 | 1 |
| **NEOSTIGMINE AND PHYSOSTIGMINE** | 0 | 1 | 1 |
| **NIMODIPINA** | 0 | 2 | 2 |
| **NP001** | 0 | 1 | 1 |
| **NUEDEXTA (DMQ)** | 1 | 0 | 1 |
| **OCTACOSANOL** | 0 | 1 | 1 |
| **OLESOXIME** | 0 | 1 | 1 |
| **ORG 2766** | 0 | 1 | 1 |
| **OZANEZUMAB** | 0 | 3 | 3 |
| **PENGH** | 0 | 1 | 1 |
| **PENTOXIFYLLINE** | 0 | 1 | 1 |
| **PERAMPANEL** | 0 | 2 | 2 |
| **PIMOZIDE** | 0 | 1 | 1 |
| **PIOGLITAZONE** | 0 | 1 | 1 |
| **PURIFIED CHLORITE** | 0 | 1 | 1 |
| **R(+) PRAMIPEXOLO** | 0 | 1 | 1 |
| **RANOLAZINA** | 1 | 0 | 1 |
| **RASAGILINA** | 0 | 3 | 3 |
| **RECOMBINANT HUMAN CILIARY NEUROTROPHIC FACTOR (RHCNTF)** | 0 | 2 | 2 |
| **RECOMBINANT HUMAN LEUKOCYTE ALPHA-2 INTERFERON** | 0 | 1 | 1 |
| **RECOMBINANT INSULIN-LIKE GROWTH FACTOR I (RHIGF-1)** | 2 | 1 | 3 |
| **RECOMBINANT METHIONYL HUMAN BRAIN DERIVED NEUROTROPHIC FACTOR (R-METHUBDNF)** | 0 | 1 | 1 |
| **RELDESEMTIV** | 0 | 1 | 1 |
| **RETIGABINA** | 1 | 0 | 1 |
| **RHGH** | 0 | 1 | 1 |
| **RILUZOLE** | 5 | 2 | 7 |
| **ROPINIROLE HYDROCHLORIDE** | 1 | 0 | 1 |
| **RX77368** | 1 | 1 | 2 |
| **SELEGILINA** | 0 | 2 | 2 |
| **SODIO FENILBUTIRATO** | 1 | 0 | 1 |
| **SODIUM PHENYLBUTYRATE-TAURURSODIOL** | 1 | 0 | 1 |
| **TALAMPANEL** | 0 | 1 | 1 |
| **TALIDOMIDE** | 0 | 2 | 2 |
| **TAMOXIFEN** | 0 | 1 | 1 |
| **TAMOXIFENE, CREATINA** | 1 | 0 | 1 |
| **TAUROURSODEOXYCHOLIC ACID (TUDCA)** | 1 | 0 | 1 |
| **TCH346** | 0 | 1 | 1 |
| **TEOFILLINE** | 1 | 0 | 1 |
| **TESTOSTERONE CYPIONATE** | 0 | 1 | 1 |
| **TILORONE** | 0 | 1 | 1 |
| **TIRASEMTIV** | 2 | 2 | 4 |
| **TOCILIZUMAB** | 1 | 0 | 1 |
| **TOFERSEN** | 0 | 2 | 2 |
| **TOPIRAMATE** | 0 | 1 | 1 |
| **TRANSFER FACTOR** | 0 | 1 | 1 |
| **TRH (THYROTROPIN RELEASING HORMONE)** | 1 | 9 | 10 |
| **UDCA** | 1 | 0 | 1 |
| **VALPROIC ACID** | 0 | 1 | 1 |
| **VERAPAMIL** | 0 | 1 | 1 |
| **XALIPRODEN** | 1 | 2 | 3 |
| **Total** | **68** | **145** | **213** |

**Supplementary table N 4.** **Mechanism of action, drugs and results**

|  |  |  |  |
| --- | --- | --- | --- |
| **Mechanisms** | **Drug** | **N positive results** | **N negative results** |
| Acetylcholinesterase inhibitor | 9-ammino-1,2,3,4-tetraidroacridina; fisostigmine; neostigmine | 0 | 3 |
| Activator of fast troponin complex | CK-2017357; reldesemtiv; tirasemtiv | 3 | 3 |
| Apoptosis | DL-3-N-butylphtialide; GM604; indinavir; minocycline; pentoxyfilline; rasagilina; sodium phenylbutyrate; TCH-346; TUDCA; UDCA | 4 | 10 |
| Autophagy | lithium carbonate | 2 | 5 |
| Bronchodilator | aminophylline; clenbuterol | 2 | 0 |
| Calcium channel blocker | pimozide; verapamil | 0 | 2 |
| D2 receptor agonist | bromocriptine; ropinirole hydrochloride | 2 | 0 |
| Decrease Endoplasmic reticulum stress | amantadine; guanabenz | 1 | 1 |
| Epigenetic /Genetic defects | lunasin; sodium phenylbutirate; tofersen; valproic acid | 1 | 4 |
| Excitotoxicity | branched-chain amino acids; ceftriaxone; dextromethorphane; gabapentin; JWSJZ decoction; lamotrigine; memantine; nimodipine; nuedexta; riluzole; talampanel | 9 | 20 |
| GABA agonist | baclofen; topiramate | 0 | 2 |
| GABA antagonist | PENGH | 0 | 1 |
| Growth factors | destran solfato; DN-1417; gangliosides; growth hormone; octacosanol; RX77368; thyrotropin releasing hormone | 4 | 17 |
| Immunomodulator | 4- Immunosuppressive drug regimen; IFN; IFNB-1A; immunoglobuline; isoprinosine; recombinant human leukocyte alpha-2 interferon; tilorone; tocilizumab | 1 | 10 |
| Iron chelator | deferiprone | 0 | 1 |
| MAO-B inhibitor | L-deprenyl; Selegiline | 0 | 3 |
| Metabolic dysfunction | inositole; L-threonine | 0 | 3 |
| Mitochondrial dysfunction | acetyl-L-carnitine; biotina (MD1003); creatine; dexpramipexole; DL-3-N-butylphtialide; EH301; olesoxime | 5 | 7 |
| Neuroinflammation | anakinra; celecoxib; cholecalciferol; corticotropina; cyclophosphamide; dimethylfumarate; DL-3-N-butylphtialide; glatiramer acetate; GM604; JWSJZ decoction; levamisole; masitinib; metilprednisolone; minocycline; NP001; ORG 2766; pioglitazone; prednisone; purified chlorite; tamoxifen; thalidomide; UDCA | 5 | 20 |
| Neuroprotective | Recombinant-Human Erythropoietin | 1 | 1 |
| Neurotrophic factors | BDNF; G-CSF; GM604; IGF-1; ozanezumab; RH-CNTF; xaliproden | 3 | 13 |
| Oxidative stress | acetylcysteine; alpha-tocopherol; brainoil; cholecalciferol; CoQ10; DL-3-N-butylphtialide; edaravone; inosine; methilcobalamine; nanocurcumina; R(+) pramipexolo; rasagilina; reduced glutathione; UDCA | 9 | 15 |
| Palliative care | morphine | 1 | 0 |
| Potassium channel activator | ezogabine; levosimendan; retigabina | 2 | 2 |
| Potassium channel blocker | 3,4 - Diaminopyridine; guanidine | 2 | 0 |
| Proteinopathy | arimoclomol | 1 | 0 |
| Sodium channel blocker | flecainide; mexiletine; ranolazina | 3 | 2 |
| Other | Ji Wu Li; lecitine; milk whey proteins; modified neurotoxin; modified snake venom; teophylline; testosterone cypionate; transfer factor | 2 | 6 |